Research programme: vitiligo therapy - SWITCH Biotech

Drug Profile

Research programme: vitiligo therapy - SWITCH Biotech

Alternative Names: SWT 05.100; SWT 05.102; SWT 05.103; SWT 05100; SWT 05102; SWT 05103; Vitiligo therapies research programme - SWITCH Biotech

Latest Information Update: 02 Jun 2005

Price : $50

At a glance

  • Originator SWITCH Biotech (CEASED)
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Vitiligo

Most Recent Events

  • 01 Mar 2005 Discontinued - Preclinical for Vitiligo in Germany (unspecified route)
  • 01 Mar 2005 SWITCH Biotech has closed down
  • 30 Mar 2004 SWITCH Biotech AG and Spirig Pharma AG have entered into an agreement to co-develop SWT 05.100 for vitiligo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top